Clinical Trial Search

Primary: Simple Kappa Coefficient of Human Epidermal Growth Factor Receptor 2 (HER-2) Status Between Local and Centralized Laboratory Assessments — 0.69 kappa coefficient…

Primary: Part I Only: Clinical Benefit Rate (CR+PR+SD≥6months) of Patients Who Received Neratinib Alone — 5 Participants

Primary: Percentage of Patients With HER2- Primary Breast Cancer Who Develop Imagable HER2+ Metastases — 13 % of participants

Primary: Cardiac Saftey — 68; 67; 66; 65 percentage of LVEF

Primary: Incidence of Treatment-emergent AE's — 16 participants

Primary: Percentage of Participants With Human Epidermal Growth Factor Receptor 2 (HER2) Status in Breast Cancer Specimens Using Immunohistochemistry (IHC) and Silver In-Situ…

Primary: Treatment-emergent Adverse Events Following Treatment With DS-8201a (Trastuzumab Deruxtecan) — 12; 12; 7; 6 Participants

Primary: Progression-free Survival(PFS) — 4.7; 3.7 Months — p=0.44

Primary: Maximum Tolerated Dose (MTD) or Maximum Feasible Dose — NA mg/kg

Primary: Pathologic Complete Response Rate (PCRR), the Percentage of Patients Who Have No Evidence of Cancer in the Breast or Lymph Nodes Following Surgery — 56 percentage of…

Primary: 16 Weeks PFS Per Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) (Cohort 1) — 1; 7 Participants

Primary: Part II: Objective Response Rate of HER2-negative Metastatic Breast Cancer (by FISH Testing) — 7 percentage of participants

Primary: Percentage of Participants With Immunohistochemical (IHC) Evaluation Between Site A and Others (Sites B, C, D and E) — 16.7; 12.5; 0.0; 8.3 percentage of participants

Primary: Number of Participants Reporting Treatment-emergent Adverse Events (TEAEs) — 3; 3; 15; 15 Participants

Primary: Objective Response Rate Per Composite Response Criteria — 7.5; 48.6; 33.3 percent of participants

Primary: Overall Response Rate (ORR) — 30 percentage of participants

Primary: Overall Tumor Response — 1; 8; 18; 29 participants

Primary: Number of Participants With and Without Progression Free Survival (PFS) Events — 92; 30 Participants

Primary: The Objective Response Rate as Defined as Stable Disease or the Rate of Complete and Partial Responses Determined on Two Consecutive Occasions Greater Than or Equal to 4…

Primary: Optimal Dose of RAD001 in Combination With Trastuzumab (Phase I) — 10 mg

Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)-Parts 1 and 2 — 1; 3; 2; 5 Participants

Primary: Part I: Progression Free Survival (PFS) by Biomarker — NA; NA; 13.963; 1.216 months

Primary: Progression-Free Survival (PFS) Based on Blinded Independent Central Review (BICR) in Participants With HER2-positive, Unresectable and/or Metastatic Breast Cancer…

Primary: Pathologic Complete Response in Breast and Axillary Lymph Nodes. — 16; 14; 21; 5 Participants

Primary: Pharmacokinetic Parameter of Maximum (Peak) Observed Serum Concentration (Cmax) Following Treatment With DS-8201a and Ritonavir - Cohort 1 — 133; 140; 121; 126 ug/mL

Primary: Percentage of Participants With Objective Response as Per Investigator Assessment According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v. 1.1)…

Primary: Dose-Limiting Toxicity (DLT) of MK-3475 in Combination With Trastuzumab — 0; 0 Participants

Primary: Invasive Disease-free Survival (DFS) — 42; 47 Participants

Primary: Percentage of Patients Who Complete Planned Oncologic Therapy Without the Development of a Cardiac Event or Asymptomatic Worsening of Cardiac Function. — 27 Participants

Primary: Objective Response Rate (ORR) (Phase II) — 0; 5; 14 Participants